10:59 AM EDT, 04/29/2025 (MT Newswires) -- Cullinan Therapeutics ( CGEM ) said Tuesday that it is starting a US study of CLN-978 in patients with Sjogren's disease, a chronic autoimmune disease.

The company said it will enroll patients with active, moderate to severe disease fulfilling the 2016 American College of Rheumatology classification criteria and who are positive for anti-Sjogren's syndrome-related antigen A/Ro antibodies and/or rheumatoid factor.

The study will evaluate the safety and tolerability of CLN-978, while secondary objectives include pharmacokinetics, pharmacodynamics, immunogenicity, and effect on disease activity, according to Cullinan.

The company said it expects to start the study in Q2.

Shares of Cullinan were up 2.4% in recent trading.

Price: 7.94, Change: +0.19, Percent Change: +2.39